Division of Otolaryngology, St. Paul's Sinus Centre, University of British Columbia, Vancouver, BC, Canada.
Eur Arch Otorhinolaryngol. 2019 Dec;276(12):3373-3381. doi: 10.1007/s00405-019-05628-w. Epub 2019 Sep 27.
Recalcitrant chronic rhinosinusitis is a persistent inflammatory condition of the sinonasal mucosa despite adequate medical therapy and sinus surgery. This study aimed to demonstrate the effectiveness and safety of dilute povidone-iodine (PVP-I) sinonasal rinses as an adjunctive therapy.
Prospective cohort study. Twenty-nine recalcitrant CRS patients with endoscopic evidence of ongoing inflammation and purulent discharge were prescribed 0.08% diluted PVP-I rinses. Changes to endoscopic modified Lund-Kennedy (MLK) scores at 7 weeks post-PVP-I rinsing served as the primary outcome measure.
The median MLK-discharge score significantly decreased in all patients by 1.50 points post-PVP-I rinsing (p value < 0.01). The total MLK score significantly decreased in all patients by 1.50 points (p value = 0.01). Up to a 17% reduction in serum inflammatory markers was measured post-PVP-I rinsing. Sinonasal culture revealed a shift from moderate-heavy growth to lighter bacterial growth overall. Subjective SNOT-22 scores significantly improved overall by ≥ 1 minimal clinically important difference (MCID > 12; baseline median = 33; follow-up median = 20; p value < 0.01; n = 22). TSH levels increased non-significantly within normal ranges (baseline median = 1.59 mU/L; follow-up median = 1.92 mU/L; p = 0.10; n = 15). Mucociliary clearance time increased non-significantly within normal ranges (baseline median = 9 min; follow-up median = 10 min; p value = 0.53; n = 17). Olfactory Sniffin'16 scores non-significantly decreased within age-related normal ranges (baseline median = 14; follow-up median = 13; p value = 0.72; n = 18).
A dilute 0.08% PVP-I sinonasal rinse as an ancillary therapy in recalcitrant CRS significantly reduces signs of infection alongside notable symptom improvement, without affecting thyroid function, mucociliary clearance or olfaction.
尽管接受了充分的药物治疗和鼻窦手术,顽固的慢性鼻-鼻窦炎仍然是一种鼻腔鼻窦黏膜的持续性炎症状态。本研究旨在证明稀碘伏(PVP-I)鼻腔冲洗作为辅助治疗的有效性和安全性。
前瞻性队列研究。29 例内镜下有持续炎症和脓性分泌物的顽固 CRS 患者被开具 0.08%稀释的 PVP-I 冲洗液处方。PVP-I 冲洗后 7 周时内镜下改良 Lund-Kennedy(MLK)评分的变化作为主要观察指标。
所有患者的 MLK-分泌物评分在 PVP-I 冲洗后中位数显著下降 1.50 分(p 值<0.01)。所有患者的总 MLK 评分中位数显著下降 1.50 分(p 值=0.01)。PVP-I 冲洗后测量到血清炎症标志物降低了 17%。鼻-鼻窦培养显示总体上从中重度生长转变为较轻的细菌生长。SNOT-22 主观评分中位数总体显著改善(≥1 个最小临床重要差异(MCID>12;基线中位数=33;随访中位数=20;p 值<0.01;n=22)。TSH 水平在正常范围内非显著升高(基线中位数=1.59 mU/L;随访中位数=1.92 mU/L;p 值=0.10;n=15)。纤毛清除时间在正常范围内非显著增加(基线中位数=9 分钟;随访中位数=10 分钟;p 值=0.53;n=17)。嗅觉 Sniffin'16 评分在年龄相关的正常范围内非显著下降(基线中位数=14;随访中位数=13;p 值=0.72;n=18)。
作为顽固 CRS 的辅助治疗,稀碘伏(0.08%)鼻腔冲洗可显著减轻感染迹象,同时显著改善症状,而不影响甲状腺功能、纤毛清除或嗅觉。